Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 3-Year EBITDA Growth Rate is 250.40% as of Jun. 2026, which is 2240% above its 10-year median of 10.70. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 809 Drug Manufacturers companies, Prestige Consumer Healthcare ranks better than 99.63% on this metric.
During the past 12 months, Prestige Consumer Healthcare's average EBITDA Per Share Growth Rate was -10.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 250.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 0.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Prestige Consumer Healthcare was 250.40% per year. The lowest was -70.60% per year. And the median was 10.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Prestige Consumer Healthcare 3-Year EBITDA Growth Rate Related Terms
PBH vs BCRX, AMLX, SUPN: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 250.40% mean?
Prestige Consumer Healthcare (PBH) has a 3-Year EBITDA Growth Rate of 250.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prestige Consumer Healthcare and its competitors. This is 2240% above median its historical median of 10.70. According to the industry distribution chart, Prestige Consumer Healthcare ranks #3 out of 809 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Prestige Consumer Healthcare's 3-Year EBITDA Growth Rate too high?
Prestige Consumer Healthcare's current 3-Year EBITDA Growth Rate of 250.40% is 2240% above median its 10-year median of 10.70. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Prestige Consumer Healthcare's value of 250.40% is 2713.5% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #3 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's 3-Year EBITDA Growth Rate compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #3 out of 809 companies for 3-Year EBITDA Growth Rate. This places Prestige Consumer Healthcare in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Prestige Consumer Healthcare's value of 250.40% is 2713.5% above this benchmark. While the company's 10-year median is 10.70 vs. the industry median of 8.90, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current 3-Year EBITDA Growth Rate of 250.40% is 2713.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prestige Consumer Healthcare and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current 3-Year EBITDA Growth Rate is 250.40%, which is 2240% above median its own 10-year median of 10.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 250.40%, which is 2240% above median its 10-year median of 10.70 and 2713.5% above the Drug Manufacturers industry median of 8.90. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current 3-Year EBITDA Growth Rate is 250.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
3-Year EBITDA Growth Rate: 250.40% (2240% above median its 10-year median of 10.70)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 2713.5% above the Drug Manufacturers median (#3 of 809)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
